Viral and Non-Viral Vector Manufacturing Market Development Fueled by Rising Demand for Personalized Medicine and Advanced Biologics

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Viral and Non-Viral Vector Manufacturing Market (Vector Type (Viral Vector (Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, Other Viral Vector), Non-Viral Vectors, (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Other Non-Viral Vector (Peptide-Based And Hybrid/Combination))), Diseases (Cancer, Genetic Disorder, And Infectious Diseases), Application (Gene Therapy (Viral Vector, Non-Viral Vector), Vaccinology (Viral Vector, Non-Viral Vector), Cell Therapy (Viral Vector, Non-Viral Vector) And Other Applications (Viral Vector, Non-Viral Vector))) - Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

According to the latest research by InsightAce Analytic, the global viral and non-viral vector manufacturing market is valued at USD 8.0 Billion in 2024, and it is expected to reach USD 56.8 Billion by the year 2034, with a CAGR of 21.9% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1263

The evolution of gene and cell therapies, particularly those employing vectors, has significantly transformed contemporary medicine. Genetic modification-based therapies have demonstrated considerable potential in treating chronic and neurological disorders. Among the delivery tools available, viral vectors remain the most widely utilized due to their superior efficiency in transporting therapeutic genes into host cells.

Adeno-associated virus (AAV) vectors, in particular, are gaining traction because of their ability to transduce both dividing and non-dividing cells, their transient expression profiles, and their low immunogenicity. Positive outcomes from clinical trials involving vector-based therapies continue to drive the advancement of both viral and non-viral vector technologies, addressing previously unmet medical needs.

The global viral and non-viral vector manufacturing market is being propelled by several critical factors, including the rising incidence of life-threatening diseases, increased adoption of next-generation therapeutic modalities, and growing demand for personalized medicine. Additional drivers include heightened investment in research and development, as well as the presence of well-established healthcare infrastructure, which together are expected to support sustained market growth. The increasing prevalence of chronic and infectious diseases further amplifies the need for gene and cell-based therapies, creating new opportunities for market participants.

Nevertheless, the market faces notable challenges that may impede expansion. These include the high costs associated with vector production, technical complexities related to scaling up manufacturing processes, and limited transfection efficiencies, particularly within non-viral systems.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Geographically, North America is anticipated to dominate the global viral and non-viral vector manufacturing market from 2020 to 2030. This is primarily attributed to ongoing research and development initiatives, coupled with the early adoption of advanced therapeutic techniques across the region.

Key market players operating in the viral and non-viral vector manufacturing market include Boehringer Ingelheim (Germany), Catalent, Inc. (US), FUJIFILM Holdings Corporation(Japan), Danaher Corporation (US), Genscript Biotech Corporation (US), Lonza Group AG (Switzerland), Merck KGaA Inc. (Germany), Oxford Biomedica plc (UK), Sartorius AG (Germany), Takara Bio Inc. (Japan), Thermo Fisher Scientific Inc. (US), Wuxi AppTec (China), Acuitas Therapeutics (Canada), Evonik Industries AG (Germany), Exelead, Inc. (US), Entos Pharmaceuticals (Canada), Genevant Sciences GmbH (Switzerland), T&T Scientific Corporation (US), Moderna, Inc. (US), CureVac N.V. (Germany), Cognate BioServices Inc. (Cobra Biologics), Genezen Laboratories, Yposkesi, Waisman Biomanufacturing, Advanced Bioscience Laboratories, Inc. (Abl Inc.), Novasep Holding S.A.S., Batavia Biosciences B.V., Biovion Oy, Sirion Biotech Gmbh., Virovek Incorporation, Biontech Imfs Gmbh, Vivebiotech S.L., Creative Biogene, Uniqure NV, Cell and Gene Therapy Catapult, Cevec. Pharmaceuticals Gmbh among others.

Key developments in the market:
• In May 2022, Catalent launched its latest UpTempo VirtuosoTM platform method for developing and CGMP production of adeno-associated viral (AAV) vectors. The UpTempo Virtuoso platform standardizes and streamlines several time-consuming procedures in AAV manufacture to drastically minimize the time from gene to clinic and enable quick clinical assessment of the first patient.
• In December 2021, GenScript ProBio (US) opened China's most prominent commercial GMP plasmid manufacturing facility. The 6,400-square-meter manufacturing plant enables the company to offer global customers a one-stop service for plasmids - from the preclinical study (IIT) to the investigational new drug (IND) filing to clinical trial and commercial manufacturing - to accelerate the innovation and development of high-quality cell and gene therapy mRNA drugs.
• In December 2021, Oxford Biomedica plc (UK) extended a commercial supply agreement with Novartis to manufacture lentiviral vectors for several Novartis CAR-T products.
• In October 2021, Matica Biotechnology, Inc, a (CDMO) specializing in the clinical and commercial production of cell and gene therapies, announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on several studies to streamline and optimize PAT technologies, automation software, and single-use platforms offered by Sartorius for large-scale vector production.
• In April 2021, Oxford Biomedica plc (UK) signed a new three-year Development & Supply Agreement ("DSA") with Boehringer Ingelheim to manufacture & supply various types of the viral vector.
• In Jan 2021, Thermo Fisher Scientific Inc. and Groupe Novasep SAS (Novasep) announced that Thermo Fisher acquired Novasep's viral vector manufacturing company in Belgium, Henogen S.A. The viral vector manufacturing division of Novasep offers contract manufacturing services for vaccines and medicines to biotechnology and major biopharma clients.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1263

Market Segments
Global Viral and Non-Viral Vector Manufacturing Market, by Vector Type, 2020-2030 (Value US$ Mn)
• Viral Vector
o Adenoviral Vector
o Retroviral Vector
o Adeno-Associated Viral Vector
o Lentiviral Vector
o Vaccinia Viral Vector
o Other Viral Vector
• Non-Viral Vectors
o Plasmid DNA
o Lipid-Based Non-Viral Vector
o Polymer-Based Non-Viral Vector
o Other Non-Viral Vector (Peptide-Based and Hybrid/Combination)
Global Viral and Non-Viral Vector Manufacturing Market, by Disease, 2020-2030 (Value US$ Mn)
• Cancer
• Genetic Disease
• Infectious Disease
• Cardiovascular Disease
• Other Diseases
Global Viral and Non-Viral Vector Manufacturing Market, by Application, 2020-2030 (Value US$ Mn)
• Gene Therapy
o Viral Vector
o Non-Viral Vector
• Vaccinology
o Viral Vector
o Non-Viral Vector
• Cell Therapy
o Viral Vector
o Non-Viral Vector
• Other Applications
o Viral Vector
o Non-Viral Vector
Global Viral and Non-Viral Vector Manufacturing Market, by Region, 2020-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Read Overview Report- https://www.insightaceanalytic.com/report/global-viral-and-non-viral-vector-manufacturing-market/1263

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.